Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP).

Journal:
Critical Care Medicine
Published:
DOI:
10.1097/ccm.0000000000007134
Affiliations:
67
Authors:
82
Go to article
Institutions Authors Share
Berry Consultants LLC, United States of America (USA)
8.000000
 0.10
Monash University, Australia
4.500000
 0.05
Auckland City Hospital (ACH), New Zealand
3.500000
 0.04
University Medical Center Utrecht (UMC Utrecht), Netherlands
3.000000
 0.04
Australian and New Zealand Intensive Care Research Centre (ANZIC-RC), Australia
3.000000
 0.04
Intensive Care National Audit & Research Centre (ICNARC), United Kingdom (UK)
3.000000
 0.04
Medical Research Institute of New Zealand (MRINZ), New Zealand
3.000000
 0.04
University of Pittsburgh (Pitt), United States of America (USA)
3.000000
 0.04
St. Vincent's University Hospital, Ireland
2.500000
 0.03
National University of Singapore (NUS), Singapore
2.000000
 0.02
University of Oxford, United Kingdom (UK)
2.000000
 0.02
Radboud University Medical Centre (Radboudumc), RU, Netherlands
2.000000
 0.02
Imperial College London (ICL), United Kingdom (UK)
2.000000
 0.02
The University of Edinburgh, United Kingdom (UK)
2.000000
 0.02
Ziauddin University, Pakistan
2.000000
 0.02
Jena University Hospital (UKJ), FSU, Germany
1.666667
 0.02
University of Toronto (U of T), Canada
1.500000
 0.02
The University of British Columbia (UBC), Canada
1.000000
 0.01
University of La Sabana (Unisabana), Colombia
1.000000
 0.01
Mahidol Oxford Tropical Medicine Research Unit (MORU), Thailand
1.000000
 0.01
St. Marianna University School of Medicine, Japan
1.000000
 0.01
The Peter Doherty Institute for Infection and Immunity (Doherty Institute), Australia
1.000000
 0.01
University of Manitoba, Canada
1.000000
 0.01
University of Bristol (UoB), United Kingdom (UK)
1.000000
 0.01
South City Hospital, Pakistan
1.000000
 0.01
European Clinical Research Alliance on Infectious Diseases (Ecraid), Netherlands
1.000000
 0.01
Fiona Stanley Hospital (FSH), Australia
1.000000
 0.01
The University of Western Australia (UWA), Australia
1.000000
 0.01
University of Pittsburgh Medical Center (UPMC), United States of America (USA)
1.000000
 0.01
University of Sherbrooke (USherbrooke), Canada
1.000000
 0.01
Queen's University Belfast (QUB), United Kingdom (UK)
1.000000
 0.01
Hospital for Advanced Medicine and Surgery (HAMS Hospital), Nepal
1.000000
 0.01
Middlemore Hospital, New Zealand
1.000000
 0.01
Unity Health Toronto, Canada
1.000000
 0.01
The University of Auckland, New Zealand
1.000000
 0.01
Raymond Poincaré University Hospital, France
1.000000
 0.01
University of Antwerp (UA), Belgium
1.000000
 0.01
Nepal Intensive Care Research Foundation (NICRF), Nepal
1.000000
 0.01
The University of Tokyo (UTokyo), Japan
1.000000
 0.01
Dr. Kamakshi Memorial Hospital, India
1.000000
 0.01
Global Coalition for Adaptive Research (GCAR), United States of America (USA)
1.000000
 0.01
IRCCS Humanitas Research Hospital, Italy
1.000000
 0.01
McGill University, Canada
1.000000
 0.01
The University of Melbourne (UniMelb), Australia
1.000000
 0.01
Dr. Ziauddin Hospital, Pakistan
1.000000
 0.01
Laval University (UL), Canada
1.000000
 0.01
King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), Saudi Arabia
1.000000
 0.01
Abbasi Shaheed Hospital, Pakistan
1.000000
 0.01
Alfred Health, Australia
0.500000
 0.01
Alfred Hospital, Australia
0.500000
 0.01
Royal Prince Alfred Hospital (RPAH), USYD, Australia
0.500000
 0.01
Sunnybrook Health Sciences Centre, U of T, Canada
0.500000
 0.01
Leibniz Institute for Natural Product Research and Infection Biology - Hans-Knöll-Institute (HKI), Germany
0.333333
 0.00
Interested in Pharmacology and Pharmaceutical Sciences?